Effect of low-dose dopamine infusion on urinary prostaglandin E2 excretion in sick, preterm infants

1988 ◽  
Vol 147 (6) ◽  
pp. 616-620 ◽  
Author(s):  
I. Seri ◽  
J. Hajdu ◽  
J. Kiszel ◽  
T. Tulassay ◽  
A. Aperia
Keyword(s):  
Prostaglandin E2 ◽  
Preterm Infants ◽  
Low Dose ◽  
Dopamine Infusion

Effect of Low-Dose Dopamine Infusion on Prolactin and Thyrotropin Secretion in Preterm Infants with Hyaline Membrane Disease

Neonatology ◽  
1985 ◽  
Vol 47 (6) ◽  
pp. 317-322 ◽  
Author(s):  
I. Sen ◽  
T. Tulassay ◽  
J. Kiszel ◽  
F. Ruppert ◽  
E. Sulyok ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Low Dose ◽  
Hyaline Membrane Disease ◽  
Dopamine Infusion ◽  
Hyaline Membrane

High versus low dose caffeine in preterm infants

2018 ◽  
Author(s):  
Petter Brattström ◽  
Chiara Russo ◽  
David Ley ◽  
Matteo Bruschettini
Keyword(s):  
Preterm Infants ◽  
Low Dose

Early Low-Dose Hydrocortisone in Very Preterm Infants: A Randomized, Placebo-Controlled Trial

Neonatology ◽  
2006 ◽  
Vol 91 (4) ◽  
pp. 217-221 ◽  
Author(s):  
F. Bonsante ◽  
G. Latorre ◽  
S. Iacobelli ◽  
V. Forziati ◽  
N. Laforgia ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Low Dose ◽  
Controlled Trial ◽  
Very Preterm Infants ◽  
Very Preterm

Not another steroid trial: early low-dose hydrocortisone in preterm infants

The Lancet ◽  
2016 ◽  
Vol 387 (10030) ◽  
pp. 1793-1794 ◽  
Author(s):  
Anne Monique Nuyt ◽  
Bernard Thébaud
Keyword(s):  
Preterm Infants ◽  
Low Dose

Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation

2012 ◽  
Vol 2 (7) ◽  
pp. 747-752 ◽  
Author(s):  
Charles H Hennekens ◽  
Scott Hetzel ◽  
Michael Pfeffer ◽  
Ricky Schneider ◽  
Steven Borzak ◽  
...  
Keyword(s):  
Prostaglandin E2 ◽  
Low Dose ◽  
Thromboxane B2 ◽  
Enteric Coated Aspirin ◽  
Enteric Coated

Hydrocortisone for Preventing Mortality and Bronchopulmonary Dysplasia in Preterm Infants with or without Chorioamnionitis Exposure: A Meta-Analysis of Randomized Trials

2020 ◽  
Author(s):  
Jianguo Zhou ◽  
Zhuowen Yu ◽  
Chao Chen
Keyword(s):  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Low Dose ◽  
Meta Analysis ◽  
Secondary Analysis ◽  
Risk Difference ◽  
Number Needed To Treat ◽  
Early Application ◽  
Infant Exposure ◽  
Significant Difference

Abstract Objective This study sought to assess whether infants exposed to chorioamnionitis are the optimal population to benefit the most from early postnatal hydrocortisone delivery in preventing bronchopulmonary dysplasia (BPD). This meta-analysis was conducted to discover the efficacy of hydrocortisone in preterm infants with and without chorioamnionitis. Study Design From the earliest available date until March 2018, studies, review articles, and papers published in PubMed, Ovid, and Web of Science were reviewed. Randomized controlled trials comparing hydrocortisone with placebo/no intervention in preterm infants with a known status of chorioamnionitis exposure were included. Result Early postpartum low-dose hydrocortisone prevents the combined outcome of neonatal BPD or death in infants weighing less than 1,000 g with chorioamnionitis exposure (odds ratio [95% confidence interval]: 0.52 [0.32–0.79]; risk difference: –0.15 [–0.24 to –0.06]; number needed to treat: 6 [4–16]) but not in infants without chorioamnionitis exposure. Further secondary analysis showed no significant difference between the hydrocortisone group and the placebo group in individual outcomes of BPD or death, regardless of infant exposure to chorioamnionitis. Conclusion Early application of low-dose hydrocortisone could potentially prevent BPD or death in infants weighing less than 1,000 g with exposure to chorioamnionitis. This finding provides the basis for further study in this target group.

Sign in / Sign up

Export Citation Format

Share Document